Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Research & Development (2018 - 2025)

Serina Therapeutics (SER) has disclosed Research & Development for 8 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 43.81% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Dec 2025, up 75.87% year-over-year, with the annual reading at $13.2 million for FY2025, 75.87% up from the prior year.
  • Research & Development hit $3.4 million in Q4 2025 for Serina Therapeutics, down from $3.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.7 million in Q3 2025 to a low of $162000.0 in Q3 2022.
  • Historically, Research & Development has averaged $1.3 million across 5 years, with a median of $542000.0 in 2021.
  • Biggest five-year swings in Research & Development: tumbled 73.46% in 2021 and later surged 336.06% in 2023.
  • Year by year, Research & Development stood at $376000.0 in 2021, then tumbled by 44.68% to $208000.0 in 2022, then surged by 336.06% to $907000.0 in 2023, then skyrocketed by 160.75% to $2.4 million in 2024, then soared by 43.81% to $3.4 million in 2025.
  • Business Quant data shows Research & Development for SER at $3.4 million in Q4 2025, $3.7 million in Q3 2025, and $3.2 million in Q2 2025.